{
  "data": {
    "drugs": {
      "nodes": [
        {
          "interactions": [
            {
              "interactionAttributes": [
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Vascular endothelial growth factor receptor inhibitor"
                },
                {
                  "name": "Alteration",
                  "value": "VEGFR1:over"
                },
                {
                  "name": "Alteration",
                  "value": "VEGFR2:over"
                },
                {
                  "name": "Clinical Trial Name",
                  "value": "Sutent"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01286896"
                },
                {
                  "name": "Cancer Type",
                  "value": "GIST"
                },
                {
                  "name": "Indication",
                  "value": "Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity."
                },
                {
                  "name": "Cancer Type",
                  "value": "Lung cancer"
                },
                {
                  "name": "Cancer Type",
                  "value": "Melanoma"
                },
                {
                  "name": "Cancer Type",
                  "value": "Thymic Carcinoma"
                },
                {
                  "name": "Cancer Type",
                  "value": "Thyroid Cancer"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "FLT1",
                "longName": "fms related receptor tyrosine kinase 1",
                "conceptId": "hgnc:3763",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "KINASE"
                  },
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  },
                  {
                    "name": "TYROSINE KINASE"
                  }
                ]
              },
              "interactionScore": 0.1275696580070323,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Dornbusch J et al., 2013, Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma., PLoS One",
                      "pmid": 24086736
                    },
                    {
                      "citation": "Terakawa T et al., 2013, Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib., Urol Oncol",
                      "pmid": 21478036
                    }
                  ],
                  "source": {
                    "sourceDbName": "CGI"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Perspicace E et al., 2013, Design, synthesis and biological evaluation of new classes of thieno[3,2-d]pyrimidinone and thieno[1,2,3]triazine as inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2)., Eur J Med Chem",
                      "pmid": 23583911
                    }
                  ],
                  "source": {
                    "sourceDbName": "DTC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenomeClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TALC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial Name",
                  "value": "Sutent"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Platelet-derived growth factor receptor inhibitor"
                },
                {
                  "name": "Approval Status",
                  "value": "late trials, preclinical"
                },
                {
                  "name": "Pathway",
                  "value": "activation"
                },
                {
                  "name": "Variant Effect",
                  "value": "gain-of-function"
                },
                {
                  "name": "Alteration",
                  "value": "PDGFRA::wildtype:."
                },
                {
                  "name": "Alteration",
                  "value": "PDGFRA:552-596,631-668,814-854"
                },
                {
                  "name": "Alteration",
                  "value": "PDGFRA:over"
                },
                {
                  "name": "Alteration",
                  "value": "PDGFRA:D842V"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01286896"
                },
                {
                  "name": "Cancer Type",
                  "value": "GIST"
                },
                {
                  "name": "Indication",
                  "value": "Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01306045"
                },
                {
                  "name": "Cancer Type",
                  "value": "Lung cancer"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: KIT or PDGFRA gene mutations will receive a drug called sunitinib, which inhibits some proteins that are thought to be key factors in the development and progression of some cancers, including kidney cancer."
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "PDGFRA",
                "longName": "platelet derived growth factor receptor alpha",
                "conceptId": "hgnc:8803",
                "geneCategories": [
                  {
                    "name": "TYROSINE KINASE"
                  },
                  {
                    "name": "KINASE"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  },
                  {
                    "name": "DRUG RESISTANCE"
                  },
                  {
                    "name": "EXTERNAL SIDE OF PLASMA MEMBRANE"
                  }
                ]
              },
              "interactionScore": 0.3513393859865807,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Yoo C et al., 2016, Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors., Cancer Res Treat",
                      "pmid": 26130666
                    },
                    {
                      "citation": "Dewaele B et al., 2008, Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation., Clin Cancer Res",
                      "pmid": 18794084
                    },
                    {
                      "citation": "Lasota J et al., 2004, A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential., Lab Invest",
                      "pmid": 15146165
                    },
                    {
                      "citation": "Heinrich MC et al., 2003, Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor., J Clin Oncol",
                      "pmid": 14645423
                    },
                    {
                      "citation": "Corless CL et al., 2005, PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib., J Clin Oncol",
                      "pmid": 15928335
                    },
                    {
                      "citation": "Prenen H et al., 2006, Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate., Clin Cancer Res",
                      "pmid": 16638875
                    },
                    {
                      "citation": "MacConaill LE et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn",
                      "pmid": 25157968
                    },
                    {
                      "citation": "Heinrich MC et al., 2006, Molecular correlates of imatinib resistance in gastrointestinal stromal tumors., J Clin Oncol",
                      "pmid": 16954519
                    },
                    {
                      "citation": "Heinrich MC et al., 2012, Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors., Clin Cancer Res",
                      "pmid": 22745105
                    },
                    {
                      "citation": "Hirota S et al., 2003, Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors., Gastroenterology",
                      "pmid": 12949711
                    },
                    {
                      "citation": "Debiec-Rychter M et al., 2005, Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants., Gastroenterology",
                      "pmid": 15685537
                    },
                    {
                      "citation": "Cassier PA et al., 2012, Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era., Clin Cancer Res",
                      "pmid": 22718859
                    }
                  ],
                  "source": {
                    "sourceDbName": "DoCM"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Prenen H et al., 2006, Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate., Clin Cancer Res",
                      "pmid": 16638875
                    },
                    {
                      "citation": "Cassier PA et al., 2012, Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era., Clin Cancer Res",
                      "pmid": 22718859
                    }
                  ],
                  "source": {
                    "sourceDbName": "CGI"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "COSMIC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenomeClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Mechanism of Action",
                  "value": "Inhibition"
                },
                {
                  "name": "Endogenous Drug",
                  "value": "false"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "DPT",
                "longName": "dermatopontin",
                "conceptId": "hgnc:3011",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  }
                ]
              },
              "interactionScore": 0.02021858730677493,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "GuideToPharmacology"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "IL4R",
                "longName": "interleukin 4 receptor",
                "conceptId": "hgnc:6015",
                "geneCategories": [
                  {
                    "name": "EXTERNAL SIDE OF PLASMA MEMBRANE"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  }
                ]
              },
              "interactionScore": 0.3571950424196904,
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Kloth JSL et al., 2018, Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib., Pharmacogenomics J",
                      "pmid": 28117434
                    }
                  ],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial Name",
                  "value": "Sutent"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Vascular endothelial growth factor receptor inhibitor"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01286896"
                },
                {
                  "name": "Cancer Type",
                  "value": "GIST"
                },
                {
                  "name": "Indication",
                  "value": "Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity."
                },
                {
                  "name": "Cancer Type",
                  "value": "Lung cancer"
                },
                {
                  "name": "Cancer Type",
                  "value": "Melanoma"
                },
                {
                  "name": "Cancer Type",
                  "value": "Thymic Carcinoma"
                },
                {
                  "name": "Cancer Type",
                  "value": "Thyroid Cancer"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "KDR",
                "longName": "kinase insert domain receptor",
                "conceptId": "hgnc:6307",
                "geneCategories": [
                  {
                    "name": "TYROSINE KINASE"
                  },
                  {
                    "name": "KINASE"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  },
                  {
                    "name": "EXTERNAL SIDE OF PLASMA MEMBRANE"
                  }
                ]
              },
              "interactionScore": 0.09055648962752716,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenomeClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TALC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Perspicace E et al., 2013, Design, synthesis and biological evaluation of new classes of thieno[3,2-d]pyrimidinone and thieno[1,2,3]triazine as inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2)., Eur J Med Chem",
                      "pmid": 23583911
                    },
                    {
                      "citation": "Choi HE et al., 2011, BRN-103, a novel nicotinamide derivative, inhibits VEGF-induced angiogenesis and proliferation in human umbilical vein endothelial cells., Bioorg Med Chem Lett",
                      "pmid": 21963305
                    },
                    {
                      "citation": "Iwata H et al., 2011, Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2., Bioorg Med Chem",
                      "pmid": 21885287
                    }
                  ],
                  "source": {
                    "sourceDbName": "DTC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenome"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TTD"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Stem cell growth factor receptor inhibitor"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Indication",
                  "value": "mast cell neoplasm"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Indication",
                  "value": "acute myeloid leukemia"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Indication",
                  "value": "gastrointestinal stromal tumor"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Biochemical"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Patient cell culture"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Clinical Study - Cohort"
                },
                {
                  "name": "Approval Status",
                  "value": "Guideline"
                },
                {
                  "name": "Alteration",
                  "value": "KIT::wildtype:."
                },
                {
                  "name": "Alteration",
                  "value": "KIT:449-514,550-592,627-664,664-714,788-828"
                },
                {
                  "name": "Alteration",
                  "value": "KIT:550-592,627-664"
                },
                {
                  "name": "Alteration",
                  "value": "KIT:H697Y"
                },
                {
                  "name": "Alteration",
                  "value": "KIT:Y553N"
                },
                {
                  "name": "Alteration",
                  "value": "KIT:550-592"
                },
                {
                  "name": "Alteration",
                  "value": "KIT:788-828"
                },
                {
                  "name": "Alteration",
                  "value": "KIT:amp"
                },
                {
                  "name": "Approval Status",
                  "value": "case report"
                },
                {
                  "name": "Pathway",
                  "value": "activation"
                },
                {
                  "name": "Variant Effect",
                  "value": "gain-of-function"
                },
                {
                  "name": "Approval Status",
                  "value": "preclinical"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01286896"
                },
                {
                  "name": "Cancer Type",
                  "value": "GIST"
                },
                {
                  "name": "Indication",
                  "value": "Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01306045"
                },
                {
                  "name": "Cancer Type",
                  "value": "Lung cancer"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: KIT or PDGFRA gene mutations will receive a drug called sunitinib, which inhibits some proteins that are thought to be key factors in the development and progression of some cancers, including kidney cancer."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT00577382"
                },
                {
                  "name": "Cancer Type",
                  "value": "Melanoma"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: SU011248 is a protein-tyrosine kinase inhibitor and acts as a c-kit inhibitor drug."
                },
                {
                  "name": "Cancer Type",
                  "value": "Thymic Carcinoma"
                },
                {
                  "name": "Clinical Trial Name",
                  "value": "Sutent"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "KIT",
                "longName": "KIT proto-oncogene, receptor tyrosine kinase",
                "conceptId": "hgnc:6342",
                "geneCategories": [
                  {
                    "name": "KINASE"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "TRANSCRIPTION FACTOR"
                  },
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  },
                  {
                    "name": "TYROSINE KINASE"
                  },
                  {
                    "name": "DRUG RESISTANCE"
                  },
                  {
                    "name": "EXTERNAL SIDE OF PLASMA MEMBRANE"
                  }
                ]
              },
              "interactionScore": 0.4906052389860809,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TALC"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Minor DR et al., 2012, Sunitinib therapy for melanoma patients with KIT mutations., Clin Cancer Res",
                      "pmid": 22261812
                    },
                    {
                      "citation": "Hodi FS et al., 2008, Major response to imatinib mesylate in KIT-mutated melanoma., J Clin Oncol",
                      "pmid": 18421059
                    },
                    {
                      "citation": "Carvajal RD et al., 2011, KIT as a therapeutic target in metastatic melanoma., JAMA",
                      "pmid": 21642685
                    },
                    {
                      "citation": "Guo J et al., 2011, Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification., J Clin Oncol",
                      "pmid": 21690468
                    }
                  ],
                  "source": {
                    "sourceDbName": "CGI"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "COSMIC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenome"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenomeClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "OncoKB"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Quek R et al., 2009, Gastrointestinal stromal tumor: a clinical overview., Hematol Oncol Clin North Am",
                      "pmid": 19248971
                    }
                  ],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Buti S et al., 2011, Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma., J Clin Oncol",
                      "pmid": 21969494
                    },
                    {
                      "citation": "Girard N et al., 2009, Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas., Clin Cancer Res",
                      "pmid": 19861435
                    },
                    {
                      "citation": "Rossi V et al., 2013, When a thymic carcinoma \"becomes\" a GIST., Lung Cancer",
                      "pmid": 23375402
                    },
                    {
                      "citation": "Schirosi L et al., 2012, Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors., Ann Oncol",
                      "pmid": 22357254
                    }
                  ],
                  "source": {
                    "sourceDbName": "DoCM"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Xu J et al., 2019, Inhibition of N822K T>A mutation-induced constitutive c-KIT activation in AML cells triggers apoptotic and autophagic pathways leading to death., Int J Med Sci",
                      "pmid": 31217744
                    },
                    {
                      "citation": "Na YS et al., 2017, Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors., Oncotarget",
                      "pmid": 29100343
                    },
                    {
                      "citation": "Liu J et al., 2022, Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib-induced KIT mutations in gastrointestinal stromal tumours., Mol Oncol",
                      "pmid": 35194937
                    },
                    {
                      "citation": "Carlino MS et al., 2014, Resistance to c-Kit inhibitors in melanoma: insights for future therapies., Oncoscience",
                      "pmid": 25594040
                    },
                    {
                      "citation": "Banks E et al., 2020, Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRÎ± inhibitor for treatment of gastrointestinal stromal tumors., Sci Transl Med",
                      "pmid": 32350132
                    },
                    {
                      "citation": "Todd JR et al., 2013, Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells., Pigment Cell Melanoma Res",
                      "pmid": 23582185
                    },
                    {
                      "citation": "Girard N et al., 2009, Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas., Clin Cancer Res",
                      "pmid": 19861435
                    },
                    {
                      "citation": "Reichardt P et al., 2016, Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial., BMC Cancer",
                      "pmid": 26772734
                    },
                    {
                      "citation": "Heinrich MC et al., 2008, Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor., J Clin Oncol",
                      "pmid": 18955458
                    },
                    {
                      "citation": "Casali PG et al., 2022, Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up., Ann Oncol",
                      "pmid": 34560242
                    },
                    {
                      "citation": "Zhao J et al., 2014, Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants., Cancer Sci",
                      "pmid": 24205792
                    },
                    {
                      "citation": "Smith BD et al., 2019, Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants., Cancer Cell",
                      "pmid": 31085175
                    },
                    {
                      "citation": "Gajiwala KS et al., 2009, KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients., Proc Natl Acad Sci U S A",
                      "pmid": 19164557
                    },
                    {
                      "citation": "Fornasarig M et al., 2020, A Novel Kindred with Familial Gastrointestinal Stromal Tumors Caused by a Rare KIT Germline Mutation (N655K): Clinico-Pathological Presentation and TKI Sensitivity., J Pers Med",
                      "pmid": 33212994
                    },
                    {
                      "citation": "Iida K et al., 2021, Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate., Cancer Discov",
                      "pmid": 33579785
                    },
                    {
                      "citation": "Liu F et al., 2019, Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors., Ther Adv Med Oncol",
                      "pmid": 31205508
                    },
                    {
                      "citation": "Garner AP et al., 2014, Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients., Clin Cancer Res",
                      "pmid": 25239608
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Mechanism of Action",
                  "value": "Inhibition"
                },
                {
                  "name": "Endogenous Drug",
                  "value": "false"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "DPP6",
                "longName": "dipeptidyl peptidase like 6",
                "conceptId": "hgnc:3010",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "TRANSPORTER"
                  },
                  {
                    "name": "ENZYME"
                  },
                  {
                    "name": "PROTEASE"
                  }
                ]
              },
              "interactionScore": 0.02143170254518142,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "GuideToPharmacology"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Platelet-derived growth factor receptor inhibitor"
                },
                {
                  "name": "Clinical Trial Name",
                  "value": "Sutent"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "PDGFRB",
                "longName": "platelet derived growth factor receptor beta",
                "conceptId": "hgnc:8804",
                "geneCategories": [
                  {
                    "name": "TYROSINE KINASE"
                  },
                  {
                    "name": "KINASE"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  }
                ]
              },
              "interactionScore": 0.1205533268166455,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenome"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Quek R et al., 2009, Gastrointestinal stromal tumor: a clinical overview., Hematol Oncol Clin North Am",
                      "pmid": 19248971
                    },
                    {
                      "citation": "Mendel DB et al., 2003, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship., Clin Cancer Res",
                      "pmid": 12538485
                    }
                  ],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TALC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Alteration",
                  "value": "RET__."
                },
                {
                  "name": "Alteration",
                  "value": "RET__TPCN1"
                },
                {
                  "name": "Alteration",
                  "value": "RET:C634W,M918T"
                },
                {
                  "name": "Indication",
                  "value": "pheochromocytoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Clinical Study"
                },
                {
                  "name": "Indication",
                  "value": "lung adenocarcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Approval Status",
                  "value": "Clinical Study - Cohort"
                },
                {
                  "name": "Approval Status",
                  "value": "preclinical"
                },
                {
                  "name": "Pathway",
                  "value": "activation"
                },
                {
                  "name": "Variant Effect",
                  "value": "gain-of-function"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Tyrosine-protein kinase receptor RET inhibitor"
                },
                {
                  "name": "Clinical Trial Name",
                  "value": "Sutent"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "RET",
                "longName": "ret proto-oncogene",
                "conceptId": "hgnc:9967",
                "geneCategories": [
                  {
                    "name": "TYROSINE KINASE"
                  },
                  {
                    "name": "KINASE"
                  },
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "DRUG RESISTANCE"
                  }
                ]
              },
              "interactionScore": 0.3968833804663227,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CGI"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenome"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Kim DW et al., 2006, An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases., J Clin Endocrinol Metab",
                      "pmid": 16849418
                    }
                  ],
                  "source": {
                    "sourceDbName": "NCI"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TALC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Wells SA Jr et al., 2010, Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer., J Clin Oncol",
                      "pmid": 20065189
                    },
                    {
                      "citation": "Couto JP et al., 2012, AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines., PLoS One",
                      "pmid": 23056499
                    },
                    {
                      "citation": "Sherman SI, 2011, Targeted therapies for thyroid tumors., Mod Pathol",
                      "pmid": 21455200
                    },
                    {
                      "citation": "Wells SA Jr et al., 2012, Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial., J Clin Oncol",
                      "pmid": 22025146
                    },
                    {
                      "citation": "Santoro M et al., 1998, Molecular biology of the MEN2 gene., J Intern Med",
                      "pmid": 9681850
                    },
                    {
                      "citation": "MacConaill LE et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn",
                      "pmid": 25157968
                    },
                    {
                      "citation": "Verbeek HH et al., 2011, The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells., J Clin Endocrinol Metab",
                      "pmid": 21470995
                    },
                    {
                      "citation": "Lam ET et al., 2010, Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer., J Clin Oncol",
                      "pmid": 20368568
                    },
                    {
                      "citation": "Elisei R et al., 2008, Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study., J Clin Endocrinol Metab",
                      "pmid": 18073307
                    },
                    {
                      "citation": "Frisk T et al., 2001, CGH alterations in medullary thyroid carcinomas in relation to the RET M918T mutation and clinical outcome., Int J Oncol",
                      "pmid": 11351254
                    },
                    {
                      "citation": "Coxon A et al., 2012, Anti-tumor activity of motesanib in a medullary thyroid cancer model., J Endocrinol Invest",
                      "pmid": 21422803
                    },
                    {
                      "citation": "Gupta-Abramson V et al., 2008, Phase II trial of sorafenib in advanced thyroid cancer., J Clin Oncol",
                      "pmid": 18541894
                    },
                    {
                      "citation": "Carr LL et al., 2010, Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation., Clin Cancer Res",
                      "pmid": 20847059
                    },
                    {
                      "citation": "Vitagliano D et al., 2010, The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells., Endocr Relat Cancer",
                      "pmid": 20943719
                    },
                    {
                      "citation": "Egawa S et al., 1998, Genotype-phenotype correlation of patients with multiple endocrine neoplasia type 2 in Japan., Jpn J Clin Oncol",
                      "pmid": 9839497
                    },
                    {
                      "citation": "Kloos RT et al., 2009, Phase II trial of sorafenib in metastatic thyroid cancer., J Clin Oncol",
                      "pmid": 19255327
                    }
                  ],
                  "source": {
                    "sourceDbName": "DoCM"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "O'Kane GM et al., 2019, A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial., Br J Cancer",
                      "pmid": 31105270
                    },
                    {
                      "citation": "Gautschi O et al., 2017, Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry., J Clin Oncol",
                      "pmid": 28447912
                    },
                    {
                      "citation": "Cooper AJ et al., 2020, Identification of a RAS-activating TMEM87A-RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer., Clin Cancer Res",
                      "pmid": 32312893
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01286896"
                },
                {
                  "name": "Cancer Type",
                  "value": "GIST"
                },
                {
                  "name": "Indication",
                  "value": "Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity."
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "PDGFB",
                "longName": "platelet derived growth factor subunit B",
                "conceptId": "hgnc:8800",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  },
                  {
                    "name": "KINASE"
                  },
                  {
                    "name": "GROWTH FACTOR"
                  },
                  {
                    "name": "CELL SURFACE"
                  }
                ]
              },
              "interactionScore": 0.3571950424196904,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenomeClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "BAP1",
                "longName": "BRCA1 associated protein 1",
                "conceptId": "hgnc:950",
                "geneCategories": [
                  {
                    "name": "ENZYME"
                  },
                  {
                    "name": "PROTEASE"
                  },
                  {
                    "name": "TUMOR SUPPRESSOR"
                  },
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  },
                  {
                    "name": "DRUG RESISTANCE"
                  }
                ]
              },
              "interactionScore": 0.1339481409073839,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01286896"
                },
                {
                  "name": "Cancer Type",
                  "value": "GIST"
                },
                {
                  "name": "Indication",
                  "value": "Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity."
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "PDGFA",
                "longName": "platelet derived growth factor subunit A",
                "conceptId": "hgnc:8799",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "KINASE"
                  },
                  {
                    "name": "GROWTH FACTOR"
                  },
                  {
                    "name": "CELL SURFACE"
                  }
                ]
              },
              "interactionScore": 0.5357925636295356,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenomeClinicalTrial"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "NOS3",
                "longName": "nitric oxide synthase 3",
                "conceptId": "hgnc:7876",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "ENZYME"
                  }
                ]
              },
              "interactionScore": 0.1530835896084387,
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Choi HE et al., 2011, BRN-103, a novel nicotinamide derivative, inhibits VEGF-induced angiogenesis and proliferation in human umbilical vein endothelial cells., Bioorg Med Chem Lett",
                      "pmid": 21963305
                    }
                  ],
                  "source": {
                    "sourceDbName": "DTC"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Eechoute K et al., 2012, Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension., Clin Pharmacol Ther",
                      "pmid": 22948895
                    }
                  ],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Sorafenib,Sunitinib,Bevacizumab,Axitinib"
                },
                {
                  "name": "Alteration",
                  "value": "VHL:."
                },
                {
                  "name": "Indication",
                  "value": "renal cell carcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "M8891 + Sunitinib"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Sunitinib + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "kidney cancer"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "VHL",
                "longName": "von Hippel-Lindau tumor suppressor",
                "conceptId": "hgnc:12687",
                "geneCategories": [
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  },
                  {
                    "name": "ENZYME"
                  },
                  {
                    "name": "DRUG RESISTANCE"
                  },
                  {
                    "name": "TRANSCRIPTION FACTOR"
                  }
                ]
              },
              "interactionScore": 0.1984416902331613,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CGI"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Jonasch E et al., 2011, Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease., Ann Oncol",
                      "pmid": 22105611
                    },
                    {
                      "citation": "Bridgeman VL et al., 2016, Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma., Mol Cancer Ther",
                      "pmid": 26487278
                    },
                    {
                      "citation": "Friese-Hamim M et al., 2024, Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models., Mol Cancer Ther",
                      "pmid": 37940144
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "PTPN12",
                "longName": "protein tyrosine phosphatase non-receptor type 12",
                "conceptId": "hgnc:9645",
                "geneCategories": [
                  {
                    "name": "PROTEIN PHOSPHATASE"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "KINASE"
                  }
                ]
              },
              "interactionScore": 0.3571950424196904,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01286896"
                },
                {
                  "name": "Cancer Type",
                  "value": "GIST"
                },
                {
                  "name": "Indication",
                  "value": "Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity."
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "PDGFD",
                "longName": "platelet derived growth factor D",
                "conceptId": "hgnc:30620",
                "geneCategories": [
                  {
                    "name": "GROWTH FACTOR"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  }
                ]
              },
              "interactionScore": 0.5357925636295356,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenomeClinicalTrial"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "M8891 + Sunitinib"
                },
                {
                  "name": "Indication",
                  "value": "renal cell carcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "TP53",
                "longName": "tumor protein p53",
                "conceptId": "hgnc:11998",
                "geneCategories": [
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "TRANSPORTER"
                  },
                  {
                    "name": "DRUG RESISTANCE"
                  },
                  {
                    "name": "TRANSCRIPTION FACTOR COMPLEX"
                  },
                  {
                    "name": "TUMOR SUPPRESSOR"
                  },
                  {
                    "name": "KINASE"
                  }
                ]
              },
              "interactionScore": 0.004731060164499211,
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Friese-Hamim M et al., 2024, Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models., Mol Cancer Ther",
                      "pmid": 37940144
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "NR1I2",
                "longName": "nuclear receptor subfamily 1 group I member 2",
                "conceptId": "hgnc:7968",
                "geneCategories": [
                  {
                    "name": "TRANSCRIPTION FACTOR"
                  },
                  {
                    "name": "NUCLEAR HORMONE RECEPTOR"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "TRANSCRIPTION FACTOR COMPLEX"
                  }
                ]
              },
              "interactionScore": 0.04741527111765802,
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Narjoz C et al., 2015, Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients., Invest New Drugs",
                      "pmid": 25344452
                    },
                    {
                      "citation": "van der Veldt AA et al., 2011, Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib., Clin Cancer Res",
                      "pmid": 21097692
                    },
                    {
                      "citation": "Beuselinck B et al., 2014, Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib., Acta Oncol",
                      "pmid": 24874929
                    },
                    {
                      "citation": "Beuselinck B et al., 2013, Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib., Br J Cancer",
                      "pmid": 23462807
                    }
                  ],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "breast cancer"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "FGFR2",
                "longName": "fibroblast growth factor receptor 2",
                "conceptId": "hgnc:3689",
                "geneCategories": [
                  {
                    "name": "TYROSINE KINASE"
                  },
                  {
                    "name": "KINASE"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  },
                  {
                    "name": "CELL SURFACE"
                  }
                ]
              },
              "interactionScore": 0.04984116870972424,
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Beuselinck B et al., 2013, Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib., Br J Cancer",
                      "pmid": 23462807
                    }
                  ],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Calfa CJ et al., 2024, Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study., JCO Precis Oncol",
                      "pmid": 38354330
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "SLCO1B3",
                "longName": "solute carrier organic anion transporter family member 1B3",
                "conceptId": "hgnc:10961",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "TRANSPORTER"
                  }
                ]
              },
              "interactionScore": 0.0857268101807257,
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Kloth JSL et al., 2018, Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib., Pharmacogenomics J",
                      "pmid": 28117434
                    }
                  ],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Mechanism of Action",
                  "value": "Inhibition"
                },
                {
                  "name": "Endogenous Drug",
                  "value": "false"
                },
                {
                  "name": "Direct Interaction",
                  "value": "false"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "DPYSL2",
                "longName": "dihydropyrimidinase like 2",
                "conceptId": "hgnc:3014",
                "geneCategories": []
              },
              "interactionScore": 0.02819960861208082,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "GuideToPharmacology"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial Name",
                  "value": "Sutent"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01286896"
                },
                {
                  "name": "Cancer Type",
                  "value": "GIST"
                },
                {
                  "name": "Indication",
                  "value": "Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity."
                },
                {
                  "name": "Cancer Type",
                  "value": "Lung cancer"
                },
                {
                  "name": "Cancer Type",
                  "value": "Melanoma"
                },
                {
                  "name": "Cancer Type",
                  "value": "Thymic Carcinoma"
                },
                {
                  "name": "Cancer Type",
                  "value": "Thyroid Cancer"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Vascular endothelial growth factor receptor inhibitor"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "FLT4",
                "longName": "fms related receptor tyrosine kinase 4",
                "conceptId": "hgnc:3767",
                "geneCategories": [
                  {
                    "name": "KINASE"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  },
                  {
                    "name": "TYROSINE KINASE"
                  }
                ]
              },
              "interactionScore": 0.1403266238077355,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TALC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenomeClinicalTrial"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Scartozzi M et al., 2013, VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib., Br J Cancer",
                      "pmid": 23511629
                    },
                    {
                      "citation": "Quek R et al., 2009, Gastrointestinal stromal tumor: a clinical overview., Hematol Oncol Clin North Am",
                      "pmid": 19248971
                    },
                    {
                      "citation": "Ravegnini G et al., 2017, An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure., Angiogenesis",
                      "pmid": 27896475
                    },
                    {
                      "citation": "Garcia-Donas J et al., 2011, Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study., Lancet Oncol",
                      "pmid": 22015057
                    },
                    {
                      "citation": "Beuselinck B et al., 2013, Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib., Br J Cancer",
                      "pmid": 23462807
                    }
                  ],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "VEGFC",
                "longName": "vascular endothelial growth factor C",
                "conceptId": "hgnc:12682",
                "geneCategories": [
                  {
                    "name": "TRANSPORTER"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "GROWTH FACTOR"
                  }
                ]
              },
              "interactionScore": 0.1190650141398968,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01286896"
                },
                {
                  "name": "Cancer Type",
                  "value": "GIST"
                },
                {
                  "name": "Indication",
                  "value": "Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity."
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "PDGFC",
                "longName": "platelet derived growth factor C",
                "conceptId": "hgnc:8801",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "GROWTH FACTOR"
                  },
                  {
                    "name": "CELL SURFACE"
                  }
                ]
              },
              "interactionScore": 1.071585127259071,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenomeClinicalTrial"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "POR",
                "longName": "cytochrome p450 oxidoreductase",
                "conceptId": "hgnc:9208",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "ENZYME"
                  }
                ]
              },
              "interactionScore": 0.2143170254518142,
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Kloth JSL et al., 2018, Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib., Pharmacogenomics J",
                      "pmid": 28117434
                    }
                  ],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "myeloid neoplasm"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Guideline"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cytarabine + Daunorubicin + Sunitinib"
                },
                {
                  "name": "Indication",
                  "value": "acute myeloid leukemia"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase Ib/II"
                },
                {
                  "name": "Indication",
                  "value": "hematologic cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Sorafenib + Sunitinib"
                },
                {
                  "name": "Indication",
                  "value": "chronic myelomonocytic leukemia"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Tyrosine-protein kinase receptor FLT3 inhibitor"
                },
                {
                  "name": "Clinical Trial Name",
                  "value": "Sutent"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01286896"
                },
                {
                  "name": "Cancer Type",
                  "value": "GIST"
                },
                {
                  "name": "Indication",
                  "value": "Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity."
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "FLT3",
                "longName": "fms related receptor tyrosine kinase 3",
                "conceptId": "hgnc:3765",
                "geneCategories": [
                  {
                    "name": "TYROSINE KINASE"
                  },
                  {
                    "name": "KINASE"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  },
                  {
                    "name": "DRUG RESISTANCE"
                  }
                ]
              },
              "interactionScore": 0.1124502911321247,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "COSMIC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenome"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenomeClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TALC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Schittenhelm MM et al., 2006, FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248)., Leukemia",
                      "pmid": 16990784
                    },
                    {
                      "citation": "Fiedler W et al., 2015, A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations., Br J Haematol",
                      "pmid": 25818407
                    },
                    {
                      "citation": "Nguyen B et al., 2017, FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors., Oncotarget",
                      "pmid": 28077790
                    },
                    {
                      "citation": "Albers C et al., 2013, The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib., Leukemia",
                      "pmid": 23392356
                    },
                    {
                      "citation": "Williams AB et al., 2013, Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors., Leukemia",
                      "pmid": 22858906
                    },
                    {
                      "citation": "von Bubnoff N et al., 2010, Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib., Leukemia",
                      "pmid": 20520641
                    },
                    {
                      "citation": "von Bubnoff N et al., 2009, FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro., Cancer Res",
                      "pmid": 19318574
                    },
                    {
                      "citation": "Young DJ et al., 2021, Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis., Blood Adv",
                      "pmid": 33914060
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Macrophage colony stimulating factor receptor inhibitor"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "CSF1R",
                "longName": "colony stimulating factor 1 receptor",
                "conceptId": "hgnc:2433",
                "geneCategories": [
                  {
                    "name": "TYROSINE KINASE"
                  },
                  {
                    "name": "KINASE"
                  },
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "CELL SURFACE"
                  }
                ]
              },
              "interactionScore": 0.03896673190032986,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Alteration",
                  "value": "CA9:over"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "CA9",
                "longName": "carbonic anhydrase 9",
                "conceptId": "hgnc:1383",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "ENZYME"
                  }
                ]
              },
              "interactionScore": 0.07654179480421938,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CGI"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Mechanism of Action",
                  "value": "Inhibition"
                },
                {
                  "name": "Endogenous Drug",
                  "value": "false"
                },
                {
                  "name": "Direct Interaction",
                  "value": "false"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "CTSV",
                "longName": "cathepsin V",
                "conceptId": "hgnc:2538",
                "geneCategories": [
                  {
                    "name": "PROTEASE"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "ENZYME"
                  }
                ]
              },
              "interactionScore": 0.08242962517377471,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "GuideToPharmacology"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Mechanism of Action",
                  "value": "Inhibition"
                },
                {
                  "name": "Endogenous Drug",
                  "value": "false"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "DRD3",
                "longName": "dopamine receptor D3",
                "conceptId": "hgnc:3024",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "G PROTEIN COUPLED RECEPTOR"
                  }
                ]
              },
              "interactionScore": 0.01020557264056258,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "GuideToPharmacology"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "EWSR1",
                "longName": "EWS RNA binding protein 1",
                "conceptId": "hgnc:3508",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "TRANSCRIPTION FACTOR"
                  },
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  }
                ]
              },
              "interactionScore": 0.2678962818147678,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "PTPRB",
                "longName": "protein tyrosine phosphatase receptor type B",
                "conceptId": "hgnc:9665",
                "geneCategories": [
                  {
                    "name": "PROTEIN PHOSPHATASE"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  }
                ]
              },
              "interactionScore": 0.2678962818147678,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Alteration",
                  "value": "HIF1A:over"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "HIF1A",
                "longName": "hypoxia inducible factor 1 subunit alpha",
                "conceptId": "hgnc:4910",
                "geneCategories": [
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "TRANSCRIPTION FACTOR"
                  },
                  {
                    "name": "TRANSPORTER"
                  },
                  {
                    "name": "ENZYME"
                  }
                ]
              },
              "interactionScore": 0.007390242256959112,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CGI"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "gastrointestinal stromal tumor"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "PTEN",
                "longName": "phosphatase and tensin homolog",
                "conceptId": "hgnc:9588",
                "geneCategories": [
                  {
                    "name": "ENZYME"
                  },
                  {
                    "name": "DRUG RESISTANCE"
                  },
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  },
                  {
                    "name": "PTEN FAMILY"
                  },
                  {
                    "name": "PROTEIN PHOSPHATASE"
                  },
                  {
                    "name": "KINASE"
                  }
                ]
              },
              "interactionScore": 0.01448088009809555,
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Na YS et al., 2017, Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors., Oncotarget",
                      "pmid": 29100343
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "CXCL8",
                "longName": "C-X-C motif chemokine ligand 8",
                "conceptId": "hgnc:6025",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  }
                ]
              },
              "interactionScore": 0.03968833804663227,
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Diekstra MH et al., 2015, Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma., Eur J Clin Pharmacol",
                      "pmid": 26387812
                    },
                    {
                      "citation": "Xu CF et al., 2015, IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma., Br J Cancer",
                      "pmid": 25695485
                    }
                  ],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Mechanism of Action",
                  "value": "Inhibition"
                },
                {
                  "name": "Endogenous Drug",
                  "value": "false"
                },
                {
                  "name": "Direct Interaction",
                  "value": "false"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "LATS2",
                "longName": "large tumor suppressor kinase 2",
                "conceptId": "hgnc:6515",
                "geneCategories": [
                  {
                    "name": "SERINE THREONINE KINASE"
                  },
                  {
                    "name": "KINASE"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  },
                  {
                    "name": "ENZYME"
                  }
                ]
              },
              "interactionScore": 0.1190650141398968,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "GuideToPharmacology"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Mechanism of Action",
                  "value": "Inhibition"
                },
                {
                  "name": "Endogenous Drug",
                  "value": "false"
                },
                {
                  "name": "Direct Interaction",
                  "value": "false"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "DPYS",
                "longName": "dihydropyrimidinase",
                "conceptId": "hgnc:3013",
                "geneCategories": [
                  {
                    "name": "ENZYME"
                  }
                ]
              },
              "interactionScore": 0.01674351761342299,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "GuideToPharmacology"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Alteration",
                  "value": "MKI67:over"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "MKI67",
                "longName": "marker of proliferation Ki-67",
                "conceptId": "hgnc:7107",
                "geneCategories": [
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  }
                ]
              },
              "interactionScore": 0.5357925636295356,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CGI"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "KDM5C",
                "longName": "lysine demethylase 5C",
                "conceptId": "hgnc:11114",
                "geneCategories": [
                  {
                    "name": "ENZYME"
                  },
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  }
                ]
              },
              "interactionScore": 0.1785975212098452,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Mechanism of Action",
                  "value": "Inhibition"
                },
                {
                  "name": "Endogenous Drug",
                  "value": "false"
                },
                {
                  "name": "Direct Interaction",
                  "value": "false"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "DRD2",
                "longName": "dopamine receptor D2",
                "conceptId": "hgnc:3023",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "G PROTEIN COUPLED RECEPTOR"
                  }
                ]
              },
              "interactionScore": 0.004235514336992377,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "GuideToPharmacology"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "YES1",
                "longName": "YES proto-oncogene 1, Src family tyrosine kinase",
                "conceptId": "hgnc:12841",
                "geneCategories": [
                  {
                    "name": "TYROSINE KINASE"
                  },
                  {
                    "name": "KINASE"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "ENZYME"
                  },
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  }
                ]
              },
              "interactionScore": 0.005151851573360919,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "DTC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "NR1I3",
                "longName": "nuclear receptor subfamily 1 group I member 3",
                "conceptId": "hgnc:7969",
                "geneCategories": [
                  {
                    "name": "NUCLEAR HORMONE RECEPTOR"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  }
                ]
              },
              "interactionScore": 0.2296253844126581,
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "De Mattia E et al., 2016, Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine., Pharmacogenomics",
                      "pmid": 27561454
                    },
                    {
                      "citation": "Beuselinck B et al., 2013, Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib., Br J Cancer",
                      "pmid": 23462807
                    }
                  ],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "CYP3A4",
                "longName": "cytochrome P450 family 3 subfamily A member 4",
                "conceptId": "hgnc:2637",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "ENZYME"
                  },
                  {
                    "name": "CYTOCHROME P450"
                  }
                ]
              },
              "interactionScore": 0.004794564327781079,
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Diekstra MH et al., 2014, Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662., Clin Pharmacol Ther",
                      "pmid": 24566734
                    },
                    {
                      "citation": "Diekstra MH et al., 2017, Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma., Pharmacogenomics J",
                      "pmid": 26810136
                    },
                    {
                      "citation": "Adams VR et al., 2007, Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors., Clin Ther",
                      "pmid": 17825686
                    }
                  ],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "VEGFA",
                "longName": "vascular endothelial growth factor A",
                "conceptId": "hgnc:12680",
                "geneCategories": [
                  {
                    "name": "DRUG RESISTANCE"
                  },
                  {
                    "name": "GROWTH FACTOR"
                  },
                  {
                    "name": "CELL SURFACE"
                  },
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  }
                ]
              },
              "interactionScore": 0.1442518440541057,
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Dornbusch J et al., 2016, Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients., J Cancer Res Clin Oncol",
                      "pmid": 26935927
                    },
                    {
                      "citation": "Scartozzi M et al., 2013, VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib., Br J Cancer",
                      "pmid": 23511629
                    },
                    {
                      "citation": "Bianconi M et al., 2016, Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma., Oncotarget",
                      "pmid": 27175586
                    },
                    {
                      "citation": "Eechoute K et al., 2012, Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension., Clin Pharmacol Ther",
                      "pmid": 22948895
                    },
                    {
                      "citation": "Ravegnini G et al., 2017, An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure., Angiogenesis",
                      "pmid": 27896475
                    },
                    {
                      "citation": "Kim JJ et al., 2012, Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib., Cancer",
                      "pmid": 21882181
                    }
                  ],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "SLC22A5",
                "longName": "solute carrier family 22 member 5",
                "conceptId": "hgnc:10969",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "TRANSPORTER"
                  },
                  {
                    "name": "EXTERNAL SIDE OF PLASMA MEMBRANE"
                  }
                ]
              },
              "interactionScore": 0.7143900848393808,
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Kloth JSL et al., 2018, Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib., Pharmacogenomics J",
                      "pmid": 28117434
                    }
                  ],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "breast cancer"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase II"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "FGFR1",
                "longName": "fibroblast growth factor receptor 1",
                "conceptId": "hgnc:3688",
                "geneCategories": [
                  {
                    "name": "TYROSINE KINASE"
                  },
                  {
                    "name": "KINASE"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "DRUG RESISTANCE"
                  },
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  }
                ]
              },
              "interactionScore": 0.02002962854689852,
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Calfa CJ et al., 2024, Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study., JCO Precis Oncol",
                      "pmid": 38354330
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "PRT1419 + Sunitinib"
                },
                {
                  "name": "Indication",
                  "value": "lung cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "PRT2527 + Sunitinib"
                },
                {
                  "name": "Indication",
                  "value": "clear cell renal cell carcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "PBRM1",
                "longName": "polybromo 1",
                "conceptId": "hgnc:30064",
                "geneCategories": [
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  }
                ]
              },
              "interactionScore": 0.1691976516724849,
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Fultang N et al., 2024, PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer., Front Oncol",
                      "pmid": 38371625
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Mechanism of Action",
                  "value": "Inhibition"
                },
                {
                  "name": "Endogenous Drug",
                  "value": "false"
                },
                {
                  "name": "Direct Interaction",
                  "value": "false"
                }
              ],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "PTK2B",
                "longName": "protein tyrosine kinase 2 beta",
                "conceptId": "hgnc:9612",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "ENZYME"
                  },
                  {
                    "name": "TYROSINE KINASE"
                  },
                  {
                    "name": "ION CHANNEL"
                  },
                  {
                    "name": "G PROTEIN COUPLED RECEPTOR"
                  },
                  {
                    "name": "KINASE"
                  }
                ]
              },
              "interactionScore": 0.02329532885345807,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "GuideToPharmacology"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "SUNITINIB",
                "conceptId": "rxcui:357977",
                "approved": true
              },
              "gene": {
                "name": "HMOX1",
                "longName": "heme oxygenase 1",
                "conceptId": "hgnc:5013",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "ENZYME"
                  },
                  {
                    "name": "DRUG RESISTANCE"
                  }
                ]
              },
              "interactionScore": 0.1190650141398968,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            }
          ]
        },
        {
          "interactions": [
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial Name",
                  "value": "JZP-8"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                }
              ],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "GABRR3",
                "longName": "gamma-aminobutyric acid type A receptor subunit rho3",
                "conceptId": "hgnc:17969",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "ION CHANNEL"
                  }
                ]
              },
              "interactionScore": 0.1077080435603989,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial Name",
                  "value": "JZP-8"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "GABA-A receptor; anion channel positive allosteric modulator"
                }
              ],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "GABRB2",
                "longName": "gamma-aminobutyric acid type A receptor subunit beta2",
                "conceptId": "hgnc:4082",
                "geneCategories": [
                  {
                    "name": "ION CHANNEL"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  }
                ]
              },
              "interactionScore": 0.07326651800329466,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial Name",
                  "value": "JZP-8"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "GABA-A receptor; anion channel positive allosteric modulator"
                }
              ],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "GABRA4",
                "longName": "gamma-aminobutyric acid type A receptor subunit alpha4",
                "conceptId": "hgnc:4078",
                "geneCategories": [
                  {
                    "name": "ION CHANNEL"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  }
                ]
              },
              "interactionScore": 0.07684049449126025,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial Name",
                  "value": "JZP-8"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "GABA-A receptor; anion channel positive allosteric modulator"
                }
              ],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "GABRB3",
                "longName": "gamma-aminobutyric acid type A receptor subunit beta3",
                "conceptId": "hgnc:4083",
                "geneCategories": [
                  {
                    "name": "ION CHANNEL"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  }
                ]
              },
              "interactionScore": 0.07778914257139927,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "GABA-A receptor; anion channel positive allosteric modulator"
                },
                {
                  "name": "Clinical Trial Name",
                  "value": "JZP-8"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                }
              ],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "GABRG2",
                "longName": "gamma-aminobutyric acid type A receptor subunit gamma2",
                "conceptId": "hgnc:4087",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "ION CHANNEL"
                  }
                ]
              },
              "interactionScore": 0.075010958908135,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial Name",
                  "value": "JZP-8"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "GABA-A receptor; anion channel positive allosteric modulator"
                }
              ],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "GABRA5",
                "longName": "gamma-aminobutyric acid type A receptor subunit alpha5",
                "conceptId": "hgnc:4079",
                "geneCategories": [
                  {
                    "name": "ION CHANNEL"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  }
                ]
              },
              "interactionScore": 0.07160136986685614,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "GABA-A receptor; anion channel positive allosteric modulator"
                }
              ],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "GABRG1",
                "longName": "gamma-aminobutyric acid type A receptor subunit gamma1",
                "conceptId": "hgnc:4086",
                "geneCategories": [
                  {
                    "name": "ION CHANNEL"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  }
                ]
              },
              "interactionScore": 0.05385402178019948,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "GABA-A receptor; anion channel positive allosteric modulator"
                },
                {
                  "name": "Clinical Trial Name",
                  "value": "JZP-8"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                }
              ],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "GABRP",
                "longName": "gamma-aminobutyric acid type A receptor subunit pi",
                "conceptId": "hgnc:4089",
                "geneCategories": [
                  {
                    "name": "ION CHANNEL"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  }
                ]
              },
              "interactionScore": 0.07975848795295368,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial Name",
                  "value": "JZP-8"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "GABA-A receptor; anion channel positive allosteric modulator"
                }
              ],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "GABRD",
                "longName": "gamma-aminobutyric acid type A receptor subunit delta",
                "conceptId": "hgnc:4084",
                "geneCategories": [
                  {
                    "name": "ION CHANNEL"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  }
                ]
              },
              "interactionScore": 0.08183013699069273,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial Name",
                  "value": "JZP-8"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "GABA-A receptor; anion channel positive allosteric modulator"
                }
              ],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "GABRA3",
                "longName": "gamma-aminobutyric acid type A receptor subunit alpha3",
                "conceptId": "hgnc:4077",
                "geneCategories": [
                  {
                    "name": "ION CHANNEL"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  }
                ]
              },
              "interactionScore": 0.07001022831425933,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial Name",
                  "value": "JZP-8"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "GABA-A receptor; anion channel positive allosteric modulator"
                }
              ],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "GABRG3",
                "longName": "gamma-aminobutyric acid type A receptor subunit gamma3",
                "conceptId": "hgnc:4088",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "ION CHANNEL"
                  }
                ]
              },
              "interactionScore": 0.07326651800329466,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "GABA-A receptor; anion channel positive allosteric modulator"
                },
                {
                  "name": "Clinical Trial Name",
                  "value": "JZP-8"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                }
              ],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "GABRE",
                "longName": "gamma-aminobutyric acid type A receptor subunit epsilon",
                "conceptId": "hgnc:4085",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "ION CHANNEL"
                  }
                ]
              },
              "interactionScore": 0.08078103267029924,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "GABA-A receptor; anion channel positive allosteric modulator"
                },
                {
                  "name": "Clinical Trial Name",
                  "value": "JZP-8"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                }
              ],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "GABRB1",
                "longName": "gamma-aminobutyric acid type A receptor subunit beta1",
                "conceptId": "hgnc:4081",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "ION CHANNEL"
                  }
                ]
              },
              "interactionScore": 0.07684049449126025,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial Name",
                  "value": "JZP-8"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "GABA-A receptor; anion channel positive allosteric modulator"
                }
              ],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "GABRA2",
                "longName": "gamma-aminobutyric acid type A receptor subunit alpha2",
                "conceptId": "hgnc:4076",
                "geneCategories": [
                  {
                    "name": "ION CHANNEL"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  }
                ]
              },
              "interactionScore": 0.06924088514597077,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "NAT2",
                "longName": "N-acetyltransferase 2",
                "conceptId": "hgnc:7646",
                "geneCategories": [
                  {
                    "name": "ENZYME"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  }
                ]
              },
              "interactionScore": 0.04375639269641208,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Specific Binding Site",
                  "value": "benzodiazepine site"
                },
                {
                  "name": "Assay Details",
                  "value": "Assay using recombinant GABA<sub>A</sub> channels with subunit composition; &alpha;2&beta;1&gamma;2."
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Positive"
                },
                {
                  "name": "Endogenous Drug",
                  "value": "false"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                }
              ],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "ARNT",
                "longName": "aryl hydrocarbon receptor nuclear translocator",
                "conceptId": "hgnc:700",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "NUCLEAR HORMONE RECEPTOR"
                  },
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  }
                ]
              },
              "interactionScore": 0.04773424657790409,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "GuideToPharmacology"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial Name",
                  "value": "JZP-8"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                }
              ],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "GABRR2",
                "longName": "gamma-aminobutyric acid type A receptor subunit rho2",
                "conceptId": "hgnc:4091",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "ION CHANNEL"
                  }
                ]
              },
              "interactionScore": 0.1615620653405984,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial Name",
                  "value": "JZP-8"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "GABA-A receptor; anion channel positive allosteric modulator"
                }
              ],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "GABRA6",
                "longName": "gamma-aminobutyric acid type A receptor subunit alpha6",
                "conceptId": "hgnc:4080",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "ION CHANNEL"
                  },
                  {
                    "name": "CLINICALLY ACTIONABLE"
                  }
                ]
              },
              "interactionScore": 0.05000730593875666,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial Name",
                  "value": "JZP-8"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                }
              ],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "GABRR1",
                "longName": "gamma-aminobutyric acid type A receptor subunit rho1",
                "conceptId": "hgnc:4090",
                "geneCategories": [
                  {
                    "name": "ION CHANNEL"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  }
                ]
              },
              "interactionScore": 0.15002191781627,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "CYP3A4",
                "longName": "cytochrome P450 family 3 subfamily A member 4",
                "conceptId": "hgnc:2637",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "ENZYME"
                  },
                  {
                    "name": "CYTOCHROME P450"
                  }
                ]
              },
              "interactionScore": 0.004698673041225458,
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev",
                      "pmid": 9187528
                    }
                  ],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "TSPO",
                "longName": "translocator protein",
                "conceptId": "hgnc:1158",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  }
                ]
              },
              "interactionScore": 0.05527123287967842,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial Name",
                  "value": "JZP-8"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "GABA-A receptor; anion channel positive allosteric modulator"
                },
                {
                  "name": "Specific Binding Site",
                  "value": "benzodiazepine site"
                },
                {
                  "name": "Assay Details",
                  "value": "Assay using recombinant GABA<sub>A</sub> channels with subunit composition; &alpha;1&beta;1&gamma;2."
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Positive"
                },
                {
                  "name": "Endogenous Drug",
                  "value": "false"
                }
              ],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "GABRA1",
                "longName": "gamma-aminobutyric acid type A receptor subunit alpha1",
                "conceptId": "hgnc:4075",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "ION CHANNEL"
                  }
                ]
              },
              "interactionScore": 0.06512579378070635,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "GuideToPharmacology"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Specific Binding Site",
                  "value": "benzodiazepine site"
                },
                {
                  "name": "Assay Details",
                  "value": "Assay using recombinant GABA<sub>A</sub> channels with subunit composition; &alpha;3&beta;1&gamma;2."
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Positive"
                },
                {
                  "name": "Endogenous Drug",
                  "value": "false"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                }
              ],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "BMAL1",
                "longName": "basic helix-loop-helix ARNT like 1",
                "conceptId": "hgnc:701",
                "geneCategories": [
                  {
                    "name": "TUMOR SUPPRESSOR"
                  },
                  {
                    "name": "TRANSCRIPTION FACTOR"
                  },
                  {
                    "name": "NUCLEAR HORMONE RECEPTOR"
                  }
                ]
              },
              "interactionScore": 0.05527123287967842,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "GuideToPharmacology"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "GABA-A receptor; anion channel positive allosteric modulator"
                },
                {
                  "name": "Clinical Trial Name",
                  "value": "JZP-8"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                }
              ],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "GABRQ",
                "longName": "gamma-aminobutyric acid type A receptor subunit theta",
                "conceptId": "hgnc:14454",
                "geneCategories": [
                  {
                    "name": "ION CHANNEL"
                  },
                  {
                    "name": "DRUGGABLE GENOME"
                  }
                ]
              },
              "interactionScore": 0.08514757497680189,
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "CLONAZEPAM",
                "conceptId": "rxcui:2598",
                "approved": true
              },
              "gene": {
                "name": "CYP1A2",
                "longName": "cytochrome P450 family 1 subfamily A member 2",
                "conceptId": "hgnc:2596",
                "geneCategories": [
                  {
                    "name": "DRUGGABLE GENOME"
                  },
                  {
                    "name": "CYTOCHROME P450"
                  },
                  {
                    "name": "ENZYME"
                  }
                ]
              },
              "interactionScore": 0.007083665596721011,
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Nims RW et al., 1997, In vivo induction and in vitro inhibition of hepatic cytochrome P450 activity by the benzodiazepine anticonvulsants clonazepam and diazepam., Drug Metab Dispos",
                      "pmid": 9193878
                    }
                  ],
                  "source": {
                    "sourceDbName": "NCI"
                  }
                }
              ]
            }
          ]
        }
      ]
    }
  }
}
